Norden Group LLC Boosts Stock Position in Intuitive Surgical, Inc. $ISRG

Key Points

• Norden Group LLC boosted its stake in Intuitive Surgical by 153.5% in Q4 to 5,342 shares (about $3.03M), while institutional investors collectively own roughly 83.64% of the company.
• Wall Street is largely constructive — ISRG has a consensus rating of Moderate Buy with an average target of $614.95 and several recent upgrades, and the company beat Q4 revenue ($2.87B) and EPS ($2.53) estimates.
• Risks include a high valuation (P/E ~59.39), YTD share weakness and trading below some analyst targets, plus insider selling of about 32,943 shares (~$17.3M) last quarter, making the stock sensitive to execution or macro setbacks.

Norden Group LLC boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 153.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,342 shares of the medical equipment provider's stock after buying an additional 3,235 shares during the period. Norden Group LLC's holdings in Intuitive Surgical were worth $3,025,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Holos Integrated Wealth LLC purchased a new stake in shares of Intuitive Surgical in the fourth quarter worth $25,000. Kilter Group LLC bought a new position in shares of Intuitive Surgical during the second quarter valued at $27,000. Greykasell Wealth Strategies Inc. purchased a new position in shares of Intuitive Surgical in the 3rd quarter worth about $27,000. Olistico Wealth LLC purchased a new position in shares of Intuitive Surgical in the 4th quarter worth about $28,000. Finally, Caitlin John LLC bought a new position in Intuitive Surgical in the 3rd quarter worth about $30,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive is taking direct control of da Vinci and Ion distribution in Southern Europe to improve sales, service and system availability — a move that should support long‑term revenue and customer uptime in a strategic region. Intuitive Surgical Extends Southern Europe Reach As Stock Trades Below Targets
• Positive Sentiment: Wall Street and retail commentary remain constructive: several recent pieces label ISRG a top pure‑play robotics buy and say analyst recommendations are generally favorable, supporting investor conviction around market leadership and long runway. Is Intuitive Surgical Inc. (ISRG) the best pure-play robotics stock to buy now?
• Positive Sentiment: Former management highlights Intuitive’s competitive moat in clinician training and ecosystem lock‑in — an important qualitative advantage that supports recurring procedure volume and replacement/system upgrade demand. Intuitive Surgical stock moat lies in training, former exec says
• Neutral Sentiment: Underlying fundamentals remain solid: the company posted a revenue and EPS beat in the most recent quarter (strong procedure growth and high margins), but those results are already priced into a premium multiple, so impact on near‑term price is mixed.
• Negative Sentiment: Shares have been under pressure — trading below some analyst targets and showing YTD weakness — which can amplify downside on headline volatility or broader market risk‑off days. Intuitive Surgical, Inc. (ISRG) Suffers a Larger Drop Than the General Market: Key Insights
• Negative Sentiment: High valuation (elevated P/E) means the stock is sensitive to execution misses, slower procedure adoption or tougher macro conditions — risks investors are currently re‑pricing into the stock.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several recent analyst reports. The Goldman Sachs Group reissued a "buy" rating and set a $714.00 price objective on shares of Intuitive Surgical in a research report on Friday, January 9th. Truist Financial lifted their target price on shares of Intuitive Surgical from $620.00 to $650.00 and gave the stock a "buy" rating in a report on Thursday, December 18th. TD Cowen upgraded shares of Intuitive Surgical to a "strong-buy" rating in a research note on Tuesday, January 27th. Citigroup upgraded shares of Intuitive Surgical from a "neutral" rating to a "buy" rating and set a $590.00 price target on the stock in a report on Wednesday, March 11th. Finally, Zacks Research raised shares of Intuitive Surgical from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $614.95.

Insider Transactions at Intuitive Surgical

In other news, EVP Myriam Curet sold 105 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $493.95, for a total value of $51,864.75. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Patricia L. Wadors sold 220 shares of the firm's stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $499.71, for a total transaction of $109,936.20. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 32,943 shares of company stock valued at $17,279,568. 0.60% of the stock is owned by company insiders.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $468.55 on Friday. The business's fifty day moving average price is $496.15 and its 200-day moving average price is $513.04. The stock has a market capitalization of $166.40 billion, a price-to-earnings ratio of 59.39, a PEG ratio of 3.63 and a beta of 1.66. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, topping the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The company had revenue of $2.87 billion during the quarter, compared to analyst estimates of $2.72 billion. During the same quarter in the previous year, the company posted $2.21 earnings per share. Intuitive Surgical's revenue was up 18.8% compared to the same quarter last year. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon's hand movements into finer, scaled motions of small instruments inside the patient. Intuitive's business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.

Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.